Cambridge-based KalVista Pharmaceuticals, a clinical stage pharmaceutical company, has announced its plans to discover, develop, and commercialize small molecule protease inhibitors to tackle diseases with unmet needs. The firm’s portfolio currently comprises of small molecule plasma kallikrein inhibitors that target hereditary angioedema (HAE) and diabetic macular edema (DME), as well as oral plasma kallikrein inhibitors. KalVista's KVD001 showed positive results in treating DME, having completed its phase 2 clinical trial, whilst its sebetralstat product candidate is currently being tested in phase 3 KONFIDENT trials as a potential oral, on-demand therapy for HAE attacks. Additionally, KalVista Pharmaceuticals' KVD824 is being developed as an oral treatment for HAE, and its Factor XIIa oral inhibitor program is in the preclinical stage of development, targeting an enzyme in HAE.
KalVista Pharmaceuticals, Inc.'s ticker is KALV
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at KalVista Pharmaceuticals, Inc.
It is https://www.kalvista.com/
KalVista Pharmaceuticals, Inc. is in the Healthcare sector
KalVista Pharmaceuticals, Inc. is in the Biotechnology industry
The following five companies are KalVista Pharmaceuticals, Inc.'s industry peers: